The moderna (flu vaccine) is still not a workable vaccine against the H1N1 coronavirus (COVID-19) – but researchers at the University of Chicago have developed a new vaccine that might be able to stop it.
The researchers say the vaccine is safe to use, easy to administer, and can prevent serious complications, such as kidney failure and liver damage, that often accompany coronaviruses.
The vaccine has not been tested in humans, but the team said in a statement that it is “an excellent candidate” to fight the coronaviral pandemic.
Researchers at the Institute for Vaccine Development at the Chicago Children’s Hospital and the Institute of Biomedical Engineering at the Perelman School of Medicine at the Johns Hopkins University in Baltimore, Maryland, developed the vaccine in collaboration with scientists from the University, Massachusetts General Hospital and Massachusetts Institute of Technology.
They tested it in mice, rats and rabbits that were infected with coronaviropsis – a coronavire that causes a severe respiratory illness.
“We think the vaccine might be a good candidate for the use in humans,” said Dr. Eric Kowalski, one of the team.
“The vaccine is not a silver bullet – we think it will work, but it is a better candidate than the older, more expensive vaccines.”
The vaccine contains a protein that inhibits the virus’s ability to grow.
That protein was discovered in 2003 by the group of scientists from Johns Hopkins and the University.
The group then created a vaccine that is more effective at preventing COVID-1 infection than a placebo.
The new vaccine is now undergoing testing in mice and is likely to be approved by the Food and Drug Administration (FDA) within two weeks, said Dr Kowalkski, who is also a professor at the National Institutes of Health.
The research is being published in the journal Vaccine.
The institute plans to announce its results in coming weeks.
“I don’t think the world is ready to be able stop coronavadavirus.
We think the current vaccine is an excellent candidate for this,” Dr Koopalks, who has led the vaccine development, said in an interview with the BBC.”
It’s not going to stop COVID.
But we think that this vaccine could be an important piece of the puzzle for stopping the pandemic.”
Researchers hope to develop the vaccine to be effective against the coronavalavirus, which has killed more than 200,000 people in the US.
The pandemic is now spreading to at least 70 countries, with more than 10,000 confirmed cases and more than 4,000 deaths.
The virus causes mild to moderate illness in people who have not developed symptoms.
Symptoms can include fever, cough, runny nose, runic plaques on the nose and throat and a rash on the face and hands.
The virus usually starts with fever and then progresses to a severe illness that includes pneumonia and death.